Ascendis Pharma (ASND) reported Q2 non-IFRS earnings Thursday of 0.90 euros ($1.04) per diluted share, up from 0.07 euros a year earlier.
A comparable analyst estimate was not readily available.
Revenue for the quarter ended June 30 was 339.3 million euros, up from 158 million euros a year earlier.
Analysts surveyed by FactSet expected 329.9 million euros.
As of June 30, the company had cash and cash equivalents of 812.3 million euros, compared with 616 million euros as of the end of last year.
Shares of Ascendis were up 2% in recent Thursday premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.